201,100 Shares in The Oncology Institute, Inc. $TOI Purchased by T3 Companies LLC

T3 Companies LLC purchased a new position in The Oncology Institute, Inc. (NASDAQ:TOI) in the 4th quarter, Holdings Channel.com reports. The firm purchased 201,100 shares of the company’s stock, valued at approximately $716,000. Oncology Institute accounts for approximately 0.9% of T3 Companies LLC’s holdings, making the stock its 22nd biggest position.

Several other hedge funds have also recently added to or reduced their stakes in the business. LPL Financial LLC raised its position in Oncology Institute by 1.5% in the fourth quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock worth $964,000 after purchasing an additional 3,900 shares in the last quarter. HighTower Advisors LLC raised its position in Oncology Institute by 5.5% in the fourth quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock worth $306,000 after purchasing an additional 4,489 shares in the last quarter. Cetera Investment Advisers raised its position in Oncology Institute by 35.0% in the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares in the last quarter. Larson Financial Group LLC raised its position in Oncology Institute by 19.7% in the fourth quarter. Larson Financial Group LLC now owns 31,468 shares of the company’s stock worth $112,000 after purchasing an additional 5,181 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its position in Oncology Institute by 141.0% in the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after purchasing an additional 7,091 shares in the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Insider Activity

In other news, insider Yale Podnos sold 23,451 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $5.38, for a total transaction of $126,166.38. Following the sale, the insider directly owned 259,527 shares of the company’s stock, valued at $1,396,255.26. This represents a 8.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 12,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were bought at an average cost of $4.75 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the insider directly owned 10,579,858 shares of the company’s stock, valued at $50,254,325.50. The trade was a 0.11% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 649,485 shares of company stock valued at $2,095,896 and have sold 119,170 shares valued at $461,183. 8.50% of the stock is owned by insiders.

Oncology Institute Trading Down 5.6%

Shares of Oncology Institute stock opened at $4.68 on Thursday. The stock has a market capitalization of $462.57 million, a price-to-earnings ratio of -12.65 and a beta of 0.37. The Oncology Institute, Inc. has a 1-year low of $2.02 and a 1-year high of $5.57. The firm’s 50-day moving average price is $3.90 and its two-hundred day moving average price is $3.42.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million. As a group, equities research analysts predict that The Oncology Institute, Inc. will post -0.17 EPS for the current year.

Analyst Ratings Changes

TOI has been the subject of several recent research reports. B. Riley Financial increased their price target on shares of Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. BTIG Research upped their price objective on shares of Oncology Institute from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Oncology Institute in a research note on Monday, March 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.